UK: Of Mice And Patents — Kymab Beats Regeneron For Insufficiency

Last Updated: 23 February 2016
Article by Beatriz San Martín

This article was first published in Lexis®PSL IP & IT analysis on 11 February 2016.

What does this case tell us about insufficiency? Dr Beatriz San Martin, partner at Fieldfisher, draws out key points and lessons from Regeneron Pharmaceuticals Inc v Kymab.

Regeneron Pharmaceuticals Inc v Kymab Ltd and another [2016] EWHC 87 (Pat) [2016] EWHC 87 (Pat)

The Patents Court made rulings in a claim concerning transgenic mice that could be used as platforms for therapeutic antibody discovery. In dismissing the claim of Regeneron Pharmaceuticals, the court held that the defendants' counterclaim for insufficiency of the patent succeeded.

What is the commercial and legal background to this judgment?

The claimant, Regeneron, brought a claim for infringement of two of its European patents (UK) — EP(UK)1,360,287 (the 287 Patent) and EP(UK)2,264,163 (the 163 Patent) — with priority dates of 16 February 2001 (the priority date), which relate to transgenic mice that can be used as platforms for therapeutic antibody discovery. Kymab, the defendant, offered various strains of transgenic mice that were alleged, either per se or through the process by which they are produced, to infringe claims 5 and 6 of the 287 Patent and claim 1 of the 163 Patent (the Claims).

Kymab denied infringement and, as is usual in these cases, counter-claimed for revocation of the patents on the basis of insufficiency, 'cross anticipation', lack of novelty, obviousness and added matter. There was a second defendant, Novo Nordisk, although the claim against it was abandoned shortly before trial. For the purposes of this article, the reference to Kymab is to both defendants.

Claim 1 of the 287 Patent was also considered in detail as being relevant to the construction of claims 5 and 6 and issues of validity.

What were the legal aspects of the insufficiency attack?

Henry Carr J provided a summary of the law on both 'classical insufficiency' and 'excessive claim breadth' insufficiency before concluding that claim 1 of the 287 Patent was invalid for insufficiency on the basis that the whole of the subject matter of claim 1 was not capable of being performed at the priority date without undue burden and without invention. According to Henry Carr J: 'the task contemplated was unprecedented and could not have been achieved, if at all, without a great deal of creative thinking at the priority date.'

As Henry Carr J had concluded that claims 5 and 6 of the 287 Patent were of considerably wider scope than claim 1 of the 287 Patent, it followed that these two other claims were also invalid for insufficiency, as well as claim 1 of the 163 Patent.

What was said about product-by-process 'obtainable by' claims?

Claims 5 and 6 of the 287 Patent were product-by-process claims which used the phrase 'obtainable by'. The products in the case of claim 5 were a genetically modified eukaryotic cells or a mouse and, in the case of claim 6, a mouse embryonic stem cell containing a genetically modified immunoglobulin heavy chain variable region gene locus.

Henry Carr J gave a helpful summary of the principles derived from Hospira UK Ltd v Genentech Inc [2014] EWHC 3857 (Pat), in respect of 'obtainable claims':

  1. their purpose is to claim a product irrespective of how it was made but with a shared characteristic which results from using a given process;
  2. the claim has to specify the characteristics being referred to;
  3. 'obtainable by' claims present clarity problems and should only be permitted if there is no alternative way of defining the product in question; and
  4. for a product to be 'obtainable by' a process it must have every characteristic which is the inevitable consequence of that process.

What was the finding on infringement?

A feature of all of the claims of the 287 Patent was 'in situ replacement' of mouse variable region immunoglobulin (Ig) genes with human variable region Ig gene segments. The judge rejected Kymab's primary submission in support of non-infringement of all claims based on its construction of 'in situ replacement' and the submission that there was no infringement because the Ig sequence in Kymab's strains of mice had not been deleted. In Henry Carr J's judgment, 'in situ replacement' meant replacing 'in the position of' and was apt to describe a positional replacement and this included both replacement through deletion and by displacement/inactivation.

He also rejected Kymab's argument that it did not infringe because the inversion and displacement of the mouse V genes did not cause them to be substantially inactivated. Kymab had failed to point him to any evidence supporting this and Kymab's own publication and a witness under cross-examination indicated otherwise. Finally, he rejected the contention that the product was not 'obtainable by' the method of claim 1 because Kymab's mice carried more orthologous sequence (300kb) than could have been carried on a single bacterial artificial chromosome (BAC). There was no evidence that each insertion by Kymab was of an orthologous sequence greater than 300kb.

Overall, Henry Carr J held that all strains of the Kymab mouse (so-called Kymouse) were or would be generated from a product within the scope of claims 5 and 6 of the 287 Patent and that Kymouse strains having both modified IgH and IgK loci were mice within the scope of claim 1 of the 163 Patent.

What was the nature and outcome of the cross-anticipation attack involving priority?

Kymab claimed 'cross-anticipation' based on alleged loss of priority, ie that the patents were anticipated by matter that retained priority in the application for the other patent. This was, in Henry Carr J's own words, a complex argument which depended on:

  1. the proposition that the patents were insufficient at the priority date, and
  2. the results of a reference to the Enlarged Board of Appeal in T 557/13, which is not yet available

Henry Carr J did not consider it necessary to decide this issue, given that he had decided that the Claims were invalid for insufficiency. He did not think this argument advanced Kymab's case any further.

Are there any points for lawyers and their clients to take away?

Technical Primers

The judge admitted at para 6 that both the subject matter of the patents and the prior art were of great technical complexity. He found the agreed technical primer very helpful as an introduction to the technology and included parts of it in his judgment. He also encouraged lawyers to cooperate on this type of approach in other complex patent cases and congratulated the lawyers in this case for achieving an agreed document.

Submission on draft judgments

In the UK, draft judgments are circulated confidentially to legal counsel for suggested corrections of obvious errors. In this case, the judge received a further written submission on behalf of Regeneron alleging that there were certain material omissions in the draft judgment which should be considered before handing down the judgment.

While Henry Carr J made it clear that he did not criticise Regeneron's counsel for raising post-judgment submissions and he emphasised that lawyers should draw the court's attention to any material omissions in a judgment rather than saving up such points for the Court of Appeal, he also warned against this becoming a frequent occurrence. He noted that post-judgment submissions should be rarely necessary and that the temptation to raise just one more point in complex high value cases should be resisted. He reiterated that the primary purpose of circulating a draft judgment was to correct typographical or other obvious errors rather than to provide an opportunity to re-argue the case.

Criticism of experts

The judge noted that professor Francis Stewart appeared to have been unduly influenced by accounts from Kymab's legal team of the problems that Regeneron experienced in its research and development. This affected the weight that the judge attached to particular aspects of his evidence, although not his evidence in general. It was also noted that professor Howard's expert evidence was based on hindsight reasoning rather than his own involvement in the relevant field at the priority date and this was taken into account when considering the issue of inventive step.

This emphasises the need to choose experts carefully such that they have the relevant expertise at the priority date. It also highlights the care that should be taken to avoid providing personal opinions or anecdotes to experts when preparing expert reports.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Beatriz San Martín
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.